By Erin Marie Daly ( April 1, 2010, 12:18 PM EDT) -- Teva Pharmaceutical Industries Ltd. has launched the latest volley in a spat over Merck & Co.'s Hyzaar and Cozaar, fighting a bid by rival Apotex Inc. to suspend a decision by U.S. regulators that granted the Israeli generics maker 180 days to exclusively sell its versions of the popular hypertension drugs....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.